Global Melanoma Drugs Market Professional Survey Report 2019
Table of Contents
Executive Summary
1 Industry Overview of Melanoma Drugs
- 1.1 Definition of Melanoma Drugs
- 1.2 Melanoma Drugs Segment by Type
- 1.2.1 Global Melanoma Drugs Production Growth Rate Comparison by Types (2014-2025)
- 1.2.2 Chemotherapy
- 1.2.3 Immunotherapy
- 1.2.4 Targeted Therapy
- 1.3 Melanoma Drugs Segment by Applications
- 1.3.1 Global Melanoma Drugs Consumption Comparison by Applications (2014-2025)
- 1.3.2 Hospitals
- 1.3.3 Clinics
- 1.3.4 Others
- 1.4 Global Melanoma Drugs Overall Market
- 1.4.1 Global Melanoma Drugs Revenue (2014-2025)
- 1.4.2 Global Melanoma Drugs Production (2014-2025)
- 1.4.3 North America Melanoma Drugs Status and Prospect (2014-2025)
- 1.4.4 Europe Melanoma Drugs Status and Prospect (2014-2025)
- 1.4.5 China Melanoma Drugs Status and Prospect (2014-2025)
- 1.4.6 Japan Melanoma Drugs Status and Prospect (2014-2025)
- 1.4.7 Southeast Asia Melanoma Drugs Status and Prospect (2014-2025)
- 1.4.8 India Melanoma Drugs Status and Prospect (2014-2025)
2 Manufacturing Cost Structure Analysis
- 2.1 Raw Material and Suppliers
- 2.2 Manufacturing Cost Structure Analysis of Melanoma Drugs
- 2.3 Manufacturing Process Analysis of Melanoma Drugs
- 2.4 Industry Chain Structure of Melanoma Drugs
3 Development and Manufacturing Plants Analysis of Melanoma Drugs
- 3.1 Capacity and Commercial Production Date
- 3.2 Global Melanoma Drugs Manufacturing Plants Distribution
- 3.3 Major Manufacturers Technology Source and Market Position of Melanoma Drugs
- 3.4 Recent Development and Expansion Plans
4 Key Figures of Major Manufacturers
- 4.1 Melanoma Drugs Production and Capacity Analysis
- 4.2 Melanoma Drugs Revenue Analysis
- 4.3 Melanoma Drugs Price Analysis
- 4.4 Market Concentration Degree
5 Melanoma Drugs Regional Market Analysis
- 5.1 Melanoma Drugs Production by Regions
- 5.1.1 Global Melanoma Drugs Production by Regions
- 5.1.2 Global Melanoma Drugs Revenue by Regions
- 5.2 Melanoma Drugs Consumption by Regions
- 5.3 North America Melanoma Drugs Market Analysis
- 5.3.1 North America Melanoma Drugs Production
- 5.3.2 North America Melanoma Drugs Revenue
- 5.3.3 Key Manufacturers in North America
- 5.3.4 North America Melanoma Drugs Import and Export
- 5.4 Europe Melanoma Drugs Market Analysis
- 5.4.1 Europe Melanoma Drugs Production
- 5.4.2 Europe Melanoma Drugs Revenue
- 5.4.3 Key Manufacturers in Europe
- 5.4.4 Europe Melanoma Drugs Import and Export
- 5.5 China Melanoma Drugs Market Analysis
- 5.5.1 China Melanoma Drugs Production
- 5.5.2 China Melanoma Drugs Revenue
- 5.5.3 Key Manufacturers in China
- 5.5.4 China Melanoma Drugs Import and Export
- 5.6 Japan Melanoma Drugs Market Analysis
- 5.6.1 Japan Melanoma Drugs Production
- 5.6.2 Japan Melanoma Drugs Revenue
- 5.6.3 Key Manufacturers in Japan
- 5.6.4 Japan Melanoma Drugs Import and Export
- 5.7 Southeast Asia Melanoma Drugs Market Analysis
- 5.7.1 Southeast Asia Melanoma Drugs Production
- 5.7.2 Southeast Asia Melanoma Drugs Revenue
- 5.7.3 Key Manufacturers in Southeast Asia
- 5.7.4 Southeast Asia Melanoma Drugs Import and Export
- 5.8 India Melanoma Drugs Market Analysis
- 5.8.1 India Melanoma Drugs Production
- 5.8.2 India Melanoma Drugs Revenue
- 5.8.3 Key Manufacturers in India
- 5.8.4 India Melanoma Drugs Import and Export
6 Melanoma Drugs Segment Market Analysis (by Type)
- 6.1 Global Melanoma Drugs Production by Type
- 6.2 Global Melanoma Drugs Revenue by Type
- 6.3 Melanoma Drugs Price by Type
7 Melanoma Drugs Segment Market Analysis (by Application)
- 7.1 Global Melanoma Drugs Consumption by Application
- 7.2 Global Melanoma Drugs Consumption Market Share by Application (2014-2019)
8 Melanoma Drugs Major Manufacturers Analysis
- 8.1 Amgen
- 8.1.1 Amgen Melanoma Drugs Production Sites and Area Served
- 8.1.2 Amgen Product Introduction, Application and Specification
- 8.1.3 Amgen Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.1.4 Main Business and Markets Served
- 8.2 Bristol-Myers Squibb
- 8.2.1 Bristol-Myers Squibb Melanoma Drugs Production Sites and Area Served
- 8.2.2 Bristol-Myers Squibb Product Introduction, Application and Specification
- 8.2.3 Bristol-Myers Squibb Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.2.4 Main Business and Markets Served
- 8.3 Roche
- 8.3.1 Roche Melanoma Drugs Production Sites and Area Served
- 8.3.2 Roche Product Introduction, Application and Specification
- 8.3.3 Roche Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.3.4 Main Business and Markets Served
- 8.4 Genentech
- 8.4.1 Genentech Melanoma Drugs Production Sites and Area Served
- 8.4.2 Genentech Product Introduction, Application and Specification
- 8.4.3 Genentech Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.4.4 Main Business and Markets Served
- 8.5 Janssen Biotech
- 8.5.1 Janssen Biotech Melanoma Drugs Production Sites and Area Served
- 8.5.2 Janssen Biotech Product Introduction, Application and Specification
- 8.5.3 Janssen Biotech Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.5.4 Main Business and Markets Served
- 8.6 Novartis
- 8.6.1 Novartis Melanoma Drugs Production Sites and Area Served
- 8.6.2 Novartis Product Introduction, Application and Specification
- 8.6.3 Novartis Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.6.4 Main Business and Markets Served
- 8.7 Pfizer
- 8.7.1 Pfizer Melanoma Drugs Production Sites and Area Served
- 8.7.2 Pfizer Product Introduction, Application and Specification
- 8.7.3 Pfizer Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.7.4 Main Business and Markets Served
- 8.8 Sanofi
- 8.8.1 Sanofi Melanoma Drugs Production Sites and Area Served
- 8.8.2 Sanofi Product Introduction, Application and Specification
- 8.8.3 Sanofi Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.8.4 Main Business and Markets Served
- 8.9 Takeda Pharma
- 8.9.1 Takeda Pharma Melanoma Drugs Production Sites and Area Served
- 8.9.2 Takeda Pharma Product Introduction, Application and Specification
- 8.9.3 Takeda Pharma Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.9.4 Main Business and Markets Served
- 8.10 Teva Pharma
- 8.10.1 Teva Pharma Melanoma Drugs Production Sites and Area Served
- 8.10.2 Teva Pharma Product Introduction, Application and Specification
- 8.10.3 Teva Pharma Melanoma Drugs Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
- 8.10.4 Main Business and Markets Served
9 Development Trend of Analysis of Melanoma Drugs Market
- 9.1 Global Melanoma Drugs Market Trend Analysis
- 9.1.1 Global Melanoma Drugs Market Size (Volume and Value) Forecast 2019-2025
- 9.2 Melanoma Drugs Regional Market Trend
- 9.2.1 North America Melanoma Drugs Forecast 2019-2025
- 9.2.2 Europe Melanoma Drugs Forecast 2019-2025
- 9.2.3 China Melanoma Drugs Forecast 2019-2025
- 9.2.4 Japan Melanoma Drugs Forecast 2019-2025
- 9.2.5 Southeast Asia Melanoma Drugs Forecast 2019-2025
- 9.2.6 India Melanoma Drugs Forecast 2019-2025
- 9.3 Melanoma Drugs Market Trend (Product Type)
- 9.4 Melanoma Drugs Market Trend (Application)
- 10.1 Marketing Channel
- 10.1.1 Direct Marketing
- 10.1.2 Indirect Marketing
- 10.3 Melanoma Drugs Customers
11 Market Dynamics
- 11.1 Market Trends
- 11.2 Opportunities
- 11.3 Market Drivers
- 11.4 Challenges
- 11.5 Influence Factors
12 Conclusion
13 Appendix
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the skin and is most common because most pigment cells are found in the skin. Mucosal melanoma is melanoma of mucous membrane of the body, including the mouth, the nasal passages, the throat, the vagina or the anus. The rare ocular melanoma or uveal melanoma occurs in the eye.
The global Melanoma Drugs market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Melanoma Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Melanoma Drugs market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Melanoma Drugs in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Melanoma Drugs manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.
The following manufacturers are covered:
Amgen
Bristol-Myers Squibb
Roche
Genentech
Janssen Biotech
Novartis
Pfizer
Sanofi
Takeda Pharma
Teva Pharma
Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India
Segment by Type
Chemotherapy
Immunotherapy
Targeted Therapy
Segment by Application
Hospitals
Clinics
Others